Curetopia

There are 10,000 rare diseases with an average market size of $150M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed biotech, with a single indication or platform. This makes the current market approach incapable of going after one of the thousands of $150M rare disease markets. However, these $150M markets are exactly where Curetopia shines and has a competitive moat.

Curetopia’s focus is specifically on this long tail of rare genetic diseases, which have a 2X higher rate of FDA approval. The family members of these rare disease patients are mission-driven warriors who have a high-risk tolerance and a 24/7 work ethic, doing whatever possible to help. Curetopia brings cures to market in a fraction of the time, with lower upfront costs.

Each rare disease uses the same underlying framework of data pooling, patient self-reporting, and feedback monitoring - Curetopia unifies this tooling and unique know-how to accelerate treatments. Family members are rewarded for contributing to the rare disease community, global researchers are incentivized to provide support, and capital is pooled together to afford drug development. Curetopia already has 8 biological targets qualified for their next set of drugs to bring to FDA trials.